Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDDA: Pharmacokinetics of Antiplatelet Drugs in Diabetic Patients
NCT02302508Phase 4Withdrawn
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Sep 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clopidogrel, prasugrel and ticagrelor in cardiovascular diseases (CVD) (4 arms), sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoint: Pharmacokinetics (AUC0-t metabolites and parent drug) at 10 hours. Planned start Sep 2019; status: withdrawn.
02
Drugs
clopidogrelprasugrelticagrelor
03
Conditions
cardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT02302508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02302508.